Understanding Anti-Nuclear Antibodies and Their Role in Autoimmune Disease Screening
Samwel Mikaye, Chief Executive Officer at Samik Medical Center, shared in the Laboratory Professionals International group on LinkedIn:
”Anti-Nuclear Antibody (ANA)
What Are They?
Anti-nuclear antibodies (ANA) are autoantibodies produced by the immune system that mistakenly attack the nucleus of the body’s own cells. The nucleus contains DNA, RNA, and associated proteins, so ANA may target these nuclear components, including nucleotides.
Why Are ANA Tested?
The ANA test is mainly used to screen for autoimmune diseases, especially:
• Systemic Lupus Erythematosus (SLE) — most commonly associated
• Sjögren’s Syndrome
• Scleroderma (Systemic Sclerosis)
• Mixed Connective Tissue Disease
• Autoimmune Thyroid Disorders (sometimes)
• Rheumatoid Arthritis (occasionally)
How Is the Test Reported?
• Results are given as titers, such as 1:40, 1:160, or 1:320.
• A higher titer suggests stronger autoimmune activity.
• The pattern seen in the lab (e.g., homogeneous, speckled, nucleolar, or centromere) may help indicate which autoimmune condition is more likely — but pattern alone is not diagnostic.
Important Interpretation Notes
• A positive ANA does not always mean disease.
• Many healthy individuals, especially elderly or those with infections, may have low-level ANA positivity.
• A negative ANA makes lupus very unlikely, but does not completely rule out all autoimmune disorders.
• Additional specific antibody tests (like anti-dsDNA, anti-Smith, anti-Ro/La) are often required to confirm diagnosis.
Key Takeaways
- ANA are antibodies that react against the body’s own cell nuclei
- Used mainly as a screening tool for autoimmune diseases like lupus
- Positive ANA alone is not enough for diagnosis — symptoms and further tests are essential
- Negative ANA reduces likelihood of lupus significantly.”
Stay updated with Hemostasis Today.
-
Oct 13, 2025, 03:53Ganesh Mohan is Organising a Webinar to Improve Awareness About Thrombophilia on World Thrombosis Day
-
Oct 13, 2025, 02:47Thomas Reiser: Don't Miss This ISTH Research Recap with Robert Sidonio, Cedric Hermans and Michael Makris
-
Oct 12, 2025, 15:39Renjith Vijayakumar Selvarani: A Heart Attack Isn’t Just a Health Scare — It’s a Medical Emergency
-
Oct 12, 2025, 11:28Is it time for GLP1 receptor agonists in VTE care?
-
Oct 12, 2025, 11:26WFH: Women and Girls with Bleeding Disorders
-
Oct 13, 2025, 03:32Wolfgang Miesbach: This Study from Children's Hospital of Philadelphia Provides Crucial Insights Into Elevidys
-
Oct 13, 2025, 02:43Lukas Meyer and Colleagues on Reperfusion-dependent Treatment Effects of Thrombectomy in Large Ischemic Infarcts
-
Oct 12, 2025, 10:14Hatim Lokhandwala: Landmark HI-PRO Trial Redefines VTE Treatment Guidelines
-
Oct 12, 2025, 07:28Roberta Gualtierotti: rFVIIIFc and rFIXFc Ensured Effective Haemostasis and Favourable Safety in Major Orthopaedic Surgery
-
Oct 12, 2025, 01:32Evaluating Drug–Drug Interactions in Cancer Patients Receiving Anticoagulants and Antineoplastics
-
Oct 13, 2025, 02:46Flora Peyvandi: First Proposed Blood Test for Chronic Fatigue Syndrome - What Scientists Think
-
Oct 13, 2025, 02:44Silvio Maresca: Honored to be part of this international research project - ThrombUS+
-
Oct 10, 2025, 12:25Robert Lewis: T Cells Are Wonderful - But They Can't Do Everything
-
Oct 9, 2025, 13:03Peter Graves: When the Bleeding Does Not Stop
-
Oct 8, 2025, 12:44Bobur Kholikov: Thrombosis Diagnostics with YHLO
-
Oct 13, 2025, 03:44Jorge Monge: It Was An Honor to Take Part in the 3rd EBA Workshop on Rare Blood Provision
-
Oct 13, 2025, 03:15Arun V. J: They Chose Death Over A Blood Transfusion — And Here’s Why I Stopped Judging Them
-
Oct 13, 2025, 03:13Rahaf Ajaj: The Persistent Gender Gap in Nobel Prizes - A Call for Greater Inclusion
-
Oct 13, 2025, 02:50Emmanuel J Favaloro: Again Promoting World Thrombosis Day - October 13
-
Oct 12, 2025, 07:38Antonio Vega With Incredible Team Led by the Great Dr Majluf